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ABSTRACT
Background: Ulcerative colitis (UC) has a recognized 
phenotypic heterogeneity. Some studies suggest that age at 
diagnosis may influence features and natural history of the disease. 
Aim: This study aimed to compare patients’, disease’s and 
treatment’s features between Portuguese patients diagnosed before 
and after the age of 40-years-old. 
Methods: Retrospective single-center study that included 310 
patients with UC, divided in two groups: Those diagnosed before 
the age of 40-years-old (early onset UC) and those diagnosed 
later than that (late onset UC). In each group features of the 
patients (gender, family history, smoking), of the disease (duration, 
extension, severity, clinical course, hospitalization, extraintestinal 
manifestations), and of treatment (oral aminosalicylates, systemic 
steroids or immunomodulators) were analyzed. Statistical analysis 
was performed using SPSSv22.0. Univariate and multivariate 
analyses were performed to assess factors associated with early 
and late onset UC. 
Results: From the analyzed patients, 207 had UC diagnosed 
before the age of 40 years old (43.5% men; mean age at diagnosis 
29.4 ± 6.9 years) and 103 were diagnosed after that age (61.2% 
men; mean age at diagnosis 51.8 ± 8.1 years). In the group 
diagnosed before 40 years old, female gender (p = 0.003), severe 
disease (p = 0.002), chronic intermittent clinical course (p = 0.026), 
and hospitalizations (p = 0.001) were significantly more frequent. 
The use of oral aminosalicylates (p = 0.032), systemic steroids (p = 
0.003) and immunomodulators (p = 0.012) were also more common 
in the early onset UC group. No differences between groups were 
found in family history, smoking, disease’s extension, extraintestinal 
manifestations, and use of biological agents. Multivariate analysis 
pointed early onset UC to be significantly associated with female 
gender (odds ratio [OR], 1.77; 95% confidence interval [CI], 1.08-
2.91; p = 0.024), chronic intermittent symptoms (OR, 2.34; 95% 
CI, 1.17-4.70; p = 0.016), and need of hospitalization (OR, 2.89; 
95% CI, 1.46-5.72; p = 0.002). 
Conclusions: When diagnosed before the age of 40-years-
old, UC preferably affects women and manifests as a more severe 
disease, with more frequent hospitalizations and chronic intermittent 
symptoms. These facts might have implications in planning timely 
and individualized future therapeutic strategies.
Key words: Ulcerative colitis. Age of diagnosis. Onset. Natural 
history.
INTRODUCTION
Ulcerative colitis (UC) is a chronic inflammatory bowel 
disease (IBD) that is believed to result from the combina-
tion of genetic factors, environmental exposures, and atyp-
ical immune responses to the gut microbiota (1). Although 
previously reported to occur according to a north-south 
gradient in Europe (2), the prevalence of UC in South-
ern European countries, namely in Portugal, seems to be 
increasing, reaching in some studies comparable values of 
those found in northern Europe countries (3,4). The esti-
mated prevalence of UC in the Portuguese population was 
71 per 100,000 in 2007 (4).
The onset of UC occurs mainly in younger individuals, 
usually in the third or fourth decade of life (5,6). Howev-
er, it is currently well described a bimodal distribution of 
disease onset with a minor second peak arising in older 
patients (7,8). As the world’s population is ageing, it is 
not unexpected that the number of patients receiving a 
diagnostic of UC later in life will soon increase. In what 
way this group of patients differs from those patients diag-
nosed earlier in life is still matter of debate. Certain older 
studies suggested that patients with a late onset UC had 
a less extensive disease but with a more aggressive clin-
ical course, requiring steroids and hospitalizations more 
frequently (9,10). Conversely, other more recent reports 
pointed that late onset UC may have a more benign clinical 
course (11,12). 
There is no doubt that UC remains a heterogeneous dis-
ease in which a specific clinical course is difficult to pre-
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dict. For this reason, the identification of certain individual 
and unambiguous factors at the moment of diagnosis may 
help in optimizing medical therapies, as well as in estab-
lishing a more accurate disease’s prognostic.
The aim of this study was to identify differences between 
patients with early onset and late onset UC, namely among 
patients’ characteristics, disease’s features, and therapeutic 
requirements, in a northern Portuguese population. As far 
as is known, this is the first published Portuguese study 




This study was designed as a single-centre, retrospective study. 
We enrolled 310 patients followed at the Inflammatory Bowel Dis-
eases Clinic at our Gastroenterology and Hepatology Department 
during the last 6 months of 2013. The information was collected 
from outpatient electronic and paper written medical records and 
inpatient history and hospital discharge summaries.
The diagnosis of ulcerative colitis was established according 
current diagnostic criteria based on clinical history, associated with 
laboratorial, endoscopic and histological signs of inflammation of 
the mucosa (13). Infectious diseases were thoroughly excluded by 
culture and microscopic stool examination.
Patients with unclassified IBD, Crohn’s disease, diverticular coli-
tis, ischemic colitis, and primary neoplasia were excluded from the 
study, as were those patients with incomplete data.
Age at the date of initial diagnosis of UC was used to classify 
patients in two different groups: Early onset UC was considered 
when patients were diagnosed at the age of 40 years or before, and 
late onset UC, when diagnosis of UC was established after 40 years 
of age.
The hospital ethics committee approved the study design. 
Description of variables
In this study, for each patient, several nominal variables were 
analysed. They were grouped in patients’, disease’s and treatment’s 
related variables.
Patient related variables included age at diagnosis of UC, gender, 
family history of IBD (defined as having first- or second-degree rel-
ative with a history of IBD) and smoking habits (divided in current 
or former smoker and non-smoker).
Disease related variables involved disease duration, disease 
extension, disease severity, clinical course, hospitalization, and 
extraintestinal manifestations. Disease extension was classified 
according to Montreal Classification in E1 – proctitis (when mucosal 
changes were found in the rectum up to 15 cm from the anus), E2 – 
left sided UC (when mucosal changes were found up to the splenic 
flexure), and E3 – extensive UC (when mucosal changes were found 
beyond splenic flexure). Disease severity was defined by the type of 
treatment administered –adapted from the classification originally 
suggested by Loftus et al. (14) for Crohn’s disease patients, but 
posteriorly used for UC patients (15,16)–, leading to the separation 
of patients in four severity grades: Mild disease (no treatment or 
salicylates), moderate to severe steroid-responsive disease (steroids 
without steroid resistance or dependence), severe steroid-refractory 
or steroid-dependence disease (immunesuppressors or biological 
agents), and medical refractory disease (submitted to surgical treat-
ment). Clinical course was categorized in one of the four predefined 
patterns proposed by the IBSEN study (17) in curve 1 (remission or 
mild severity of intestinal symptoms after initial high activity), curve 
2 (increase in the severity of intestinal symptoms after initial activ-
ity), curve 3 (chronic continuous symptoms), and curve 4 (chronic 
intermittent symptoms). Hospitalization was defined as admission at 
the hospital when patients fulfilled the Truelove and Witts’ criteria 
for acute severe UC, as recommended by prevailing guidelines (18). 
Extraintestinal manifestations included joint, skin, ocular, thrombo-
embolic or hepatobiliary manifestations of UC. 
Treatment-associated variables comprised the use of topical or 
oral aminosalicylates, need of systemic steroids and use of immuno-
modulators (including azathioprine, 6-mercaptopurine, methotrexate 
or biological agents, namely infliximab or adalimumab). 
Statistical analysis
The results were analysed using Statistical Packages for Social 
Sciences (SPSS) software, version 22.0 (IBM, Armonk, New 
York, USA). When descriptive analysis was performed, data were 
expressed as mean ± standard deviation for continuous variables or 
as absolute frequency (number) and relative frequency (percentag-
es) for categorical variables. For comparative analysis, independent 
samples t-test, Qui-square and Fisher’s exact tests were used as 
appropriate. Stepwise binary logistic model was performed to assess 
factors associated with early onset UC. Multivariable models were 
adjusted for potential confounding factors. Statistical significance 
was considered when the p value was less than 0.05, and all reported 
P values are two-tailed.
RESULTS
Demographic characteristics
From the patients who had been under periodic fol-
low-up at the Inflammatory Bowel Disease Clinic of our 
centre, 310 patients with UC were enrolled in this study. 
They were purposely divided into two different groups of 
patients: Those with UC diagnosed at the age of 40 years or 
before (early onset UC) and those with an established diag-
nosis of UC after 40 years of age (late onset UC) (Fig. 1). 
The mean age at diagnosis was 29.4 ± 6.9 years (range 
from 10 to 40 years) in the early onset group and 51.7 ± 
8.1 years (range from 41 to 74) in the late onset group. The 
distribution of patients by age at diagnosis of UC was also 
analysed (Fig. 2).
From the 207 patients included in the early onset group, 
90 patients (43.5%) were men and 117 (56.5%) were 
women. Conversely, the late onset group comprised 103 
patients, in which 63 (61.2%) were men and 40 (38.8%) 
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were women. These differences were statistically signifi-
cant (p = 0.003; OR = 1.46) (Table I). The percentage of 
women diagnosed with UC is higher than men’s in the first 
decades of life. However, as time goes by, a diagnosis of 
UC is increasingly established in men and less frequently 
in women (Fig. 3). The male to female ratio was 1:1.3 in 
the younger group and 1.6:1 in the older group.
All the analysed patients in our series were Caucasian.
Regarding family history of IBD, 14 (6.8%) out of 207 
patients diagnosed before the age of 40 years had at least 
one first- or second-degree relative with IBD. On the other 
hand, only 4 (3.8%) out of 103 patients diagnosed later 
in life had an affected relative. There were no significant 
differences between the two groups (p = 0.44).
In relation to smoking habits, 45 (21.7%) patients in the 
early onset group and 27 (26.2%) patients in the late onset 
group were current or former smokers. Once again no sig-
nificant differences were found between groups (p = 0.38).
Characteristics of the disease
Before proceeding further analysis, we confirmed that 
there were no differences in disease’s duration between 
both groups. In fact, the mean duration of disease in the 
younger group was 9.8 ± 7.5 years, while in the older 
group it was 8.4 ± 6.1 years. These differences were not 
significant (p = 0.098) (Table II).
Extension and severity of the disease, clinical course, 
need of hospital admission for acute severe exacerbation 
and extraintestinal manifestations were then analysed.
In the early onset group, 75 (36.2%) patients had iso-
lated proctitis, 70 (33.8%) patients had left sided colitis, 
and 62 (30.0%) had extensive colitis. Similarly, in the late 
onset group, 40 (38.8%) patients had proctitis, 39 (37.9%) 
had left sided colitis, and 24 (23.3%) had extensive colitis. 
No differences were found between the two groups regard-
ing this topic (p = 0.46).
Regarding the severity of the disease, 105 (50.7%) 
patients with early onset UC had mild disease, 52 (25.1%) 
had moderate to severe steroid-responsive disease, and 
50 (24.2%) had severe steroid-refractory or steroid-de-
718 patients followed at the  
Inflammatory Bowel Disease Clinic
103 UC patients diagnosed 
after the age of 40 (late 
onset group)
207 UC patients diagnosed 
at the age of 40 or before 
(early onset group)
408 patients excluded from 
analysis (meeting exclusion 
criteria; incomplete data)
Fig. 1. Study design and patients’ grouping.
Fig. 2. Age distribution of patients according to the age at diagnosis 
of UC.
Fig. 3. Percentage of men and women in each decade of diagnosis.
Table I. Demographic characteristics: Comparison between 






Gender – no. (%)
0.003* Male 90 (43.5) 63 (61.2)
 Female 117 (56.5) 40 (38.8)
Family history – no. (%)
0.44 Yes 14 (6.8) 4 (3.8)
 No 193 (92.2) 99 (96.2)
Smoking – no. (%)
0.38 Current or former smoker 45 (21.7) 27 (26.2)
 Non-smoker 162 (78.3) 76 (73.8)
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pendence disease. On the contrary, in the late onset UC 
group, 73 (70.9%) patients had mild disease, 17 (16.5%) 
had moderate to severe steroid-responsive disease, and 
13 (11.6%) had severe steroid-refractory or steroid-de-
pendence disease. Only 1 patient (1%) had a colectomy 
performed, which indication was dysplasia and not medi-
cal refractory disease. These differences were statistically 
significant (p = 0.003).
Concerning the clinical course of the disease, four 
different curves of disease activity were considered, as 
described in methods. In those patients diagnosed at or 
before the age of 40 years, 110 (53.1%) had remission 
or mild severity of symptoms after initial high activity 
(curve 1), 19 (9.2%) showed increase in the severity of 
symptoms after initial low activity (curve 2), 26 (12.6%) 
referred chronic continuous symptoms (curve 3), and 
52 (25.1%) patients had chronic intermittent symptoms 
(curve 4). On the other hand, from those patients diag-
nosed with UC after the age of 40 years, 69 (66.9%) had 
their disease course represented in curve 1, 12 (11.7%) in 
curve 2, 10 (9.7%) in curve 3 and 12 (11.7%) in curve 4. 
Comparative analysis showed again significant differenc-
es (p = 0.026).
The need of hospitalization, when patients fulfilled the 
Truelove and Witts’ criteria for severe acute colitis, was 
another studied topic. In the early onset UC group, 60 
patients (29%) required hospitalization; alternatively, in 
the late onset UC group, only 12 patients (11.7%) needed 
hospital admission (p = 0.001; OR = 2.49).
When extraintestinal manifestations were evaluated, 
we found that 32 patients (15.5%) in the early onset UC 
group had at least another affected organ: 24 patients 
had arthritis, 5 patients had skin conditions (1 pyoderma 
gangrenosum and 4 erythema nodosum), and 3 had epis-
cleritis. On the other hand, in the late onset group, only 
13 patients (12.6%) had extraintestinal involvement: 10 
patients had arthritis, 2 had history of thromboembolic 
events, and 1 had episcleritis. These findings were not 
significantly different between the two groups of patients 
(p = 0.50). 






Duration (years ± SD2)
0.098
 9.8 ± 7.5 8.4 ± 6.1
Extension – no. (%)
0.46
 Proctitis (E1) 75 (36.2) 40 (38.8)
 Left sided colitis (E2) 70 (33.8) 39 (37.9)
 Extensive colitis (E3) 62 (30.0) 24 (23.3)
Severity – no. (%)
0.003*
 Mild 105 (50.7) 73 (70.9)
 Moderate to severe steroid-responsive 52 (25.1) 17 (16.5)
 Severe steroid-dependent or steroid-refractory 50 (24.2) 13 (12.6)
 Medical refractory 0 (0.0) 0 (0.0)
Clinical course – no. (%)1
0.026*
 Curve 1 110 (53.1) 69 (66.9)
 Curve 2 19 (9.2) 12 (11.7)
 Curve 3 26 (12.6) 10 (9.7)
 Curve 4 52 (25.1) 12 (11.7)
Hospitalization – no. (%)
0.001* Yes 60 (29.0) 12 (11.7)
 No 147 (71.0) 91 (88.3)
Extraintestinal manifestations – no. (%)
0.50 Yes 32 (15.5) 13 (12.6)
 No 175 (84.5) 90 (87.4)
1According to IBSEN Study (17): curve 1 (remission or mild severity of intestinal symptoms after initial high activity), curve 2 (increase in the severity of intestinal symptoms 
after initial activity), curve 3 (chronic continuous symptoms), and curve 4 (chronic intermittent symptoms). 2Standard deviation.
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Characteristics of the treatment
All the patients included in our study required topical 
aminosalicylates at some time during the clinical course 
of the disease, independently of the age of onset of symp-
toms.
When the use of oral aminosalicylates was analysed, 
we verified that 194 patients (93.7%) in the early onset 
UC group have used them versus 89 patients (86.4%) 
in the late onset UC group (p = 0.032; OR = 1.09) 
(Table III).
Regarding the use of systemic steroids for the treat-
ment of colorectal inflammation, it was required in 97 
patients (46.9%) in the early onset UC group versus only 
30 patients (29.1%) in the late onset UC group (p = 0.003; 
OR = 1.61).
Finally, we evaluated the use of immunomodulators 
in both groups. In the early onset UC group, 49 patients 
(23.7%) needed azathioprine or 6-mercaptopurine, where-
as only 12 patients (11.7%) in the late onset UC needed this 
type of medical therapy. Additionally, 15 patients (7.2%) 
in the early onset UC group required treatment with bio-
logical agents (13 infliximab and 2 adalimumab), while 
6 patients (5.8%) in the late onset UC group used anti-
TNF agents (all of them used infliximab). Although the 
use of thiopurines was significantly more common in the 
early onset UC group (p = 0.012; OR = 2.03), differences 
between groups regarding the use of biological agents were 
not statistically significant (p = 0.64).
Factors associated with early onset UC
Stepwise binary logistic model was performed to assess 
factors associated with early onset UC.
Potential confounding factors that were adjusted for in 
the multivariate analysis included the gender of the patient, 
the severity and clinical course of the disease, the need 
of hospitalization, and the use of oral aminosalicylates, 
systemic steroids or thiopurines.
Multivariate analysis revealed that female gender (OR 
1.77; 95% CI 1.08-2.91), chronic intermittent clinical 
course (OR 2.89; 95% CI 1.46-5.72), and need of hospi-
talization (OR 2.34; 95% CI 1.17-4.70) were associated 
with early onset of UC (Fig. 4). In other words, when UC 
is diagnosed before the age of 40 years, there are 77% 
more chances for the disease to affect a woman than a man. 
Also, a patient with early onset UC has 2.34 more chances 
of requiring hospitalization than a patient diagnosed after 
the 40 years old. Finally, early onset UC patients have 2.89 
more chances of developing chronic intermittent symp-
toms than patients with late onset UC.
In the performed analysis, severity of the disease, and 
use of oral aminosalicylates, systemic steroids or thio-
purines were not associated with this earlier form of the 
disease.
Table III. Treatment’s characteristics: Comparison between 






Oral aminosalicylates – no. (%)
0.032*
194 (93.7) 89 (86.4)
Systemic steroids – no. (%)
0.003*
97 (46.9) 30 (29.1)
Thiopurines – no. (%)
0.012*
49 (23.7) 12 (11.7)
Biological agents – no. (%)
0.64
15 (7.2) 6 (5.8)
Fig. 4. Odds ratio for early onset UC.
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DISCUSSION
Being a heterogeneous disease by itself, UC is further 
diversified by genetic background, environmental factors 
and gut microbiota, which vary among different popu-
lations. Thus, the recognition of features of the disease 
in specific populations is of major importance when an 
improved and individualized treatment is to be achieved. 
As the incidence of UC seems to be increasing and the 
world population is ageing, it is appropriate to expect a 
growing number of patients being diagnosed with UC in 
later decades of life. While some studies describing specif-
ic demographic and clinical characteristics of Portuguese 
patients with UC have been published (15,16), studies 
specifically addressing the differences between Portuguese 
patients with early and late onset UC are lacking. 
The concepts of early and late onset UC have been 
inconsistently defined in the literature. While some authors 
defined early onset UC when diagnosis was established 
anytime between the age of 0-20 years (3,19-21), and 
late onset UC when disease was identified after the age 
of 60-95 (19,22-24) other studies commonly consider the 
age of 40 years old a reasonable cut-off point (25). In fact, 
according to the World Health Organization, the transi-
tion from early adulthood and late adulthood occurs when 
individuals reach 40 years old. Even more important is the 
fact that Viena Classification and, more recently, Montreal 
Classification, commonly used to classify Crohn’s disease 
patients, use that same cut-off point when defining differ-
ent groups of patients (26). Bearing these facts in mind, 
and as in our group of patients only six were diagnosed 
before or at the age of 16 years, it seemed legitimate to 
group our patients in the previous defined groups: Early 
onset UC when disease was identified before or at the age 
of 40 years old and late onset UC when disease was diag-
nosed later in life. 
Although not completely understood, the impact of 
age at diagnosis in the natural history and features of UC 
can be better explained when genetic influences, environ-
mental factors, gut microbiota composition and immune 
responses according to age are taken into consideration. 
The role of genetic factors in early onset UC is thought 
to be greater than in late onset disease when family his-
tory of IBD is analysed. In our study, despite no statisti-
cal significance was reached, family history of IBD was 
almost double in the early onset group than in the late onset 
group, which is concordant with other previous studies 
(7,23,27). The link between genetic influences and onset 
of UC is further strengthened by genome-wide associ-
ation studies, which have identified at least 23 specific 
gene polymorphisms associated with a higher susceptibil-
ity of developing UC (28). Some of those genes, namely 
multidrug-resistant transporter 1 (MDR1) gene, important 
for the barrier function of the intestinal epithelium, were 
associated with a younger age of onset and a more severe 
course of disease (28). Regarding genetic influence on age 
of onset, and according to our results, we can further pre-
sume that female gender is more frequently associated with 
early onset disease, while male gender seems to predispose 
to late onset UC, which is accordant with other previous 
studies (2,23,27).
Though with variable degree of evidence, different envi-
ronmental factors, such as smoking, nonsteroidal anti-in-
flammatory drugs, prior appendectomy, previous antibiotic 
use and urbanization, have been related to IBD expression 
and age of onset of the disease (29). In the current study, 
only smoking status was analysed between groups. Pre-
vious studies have reported the protective effect of active 
smoking on the development and clinical course of UC 
(30,31). As shown in our results, smoking habits do not 
seem to influence the age of onset of the disease. However, 
these results need to be interpreted carefully because no 
distinction between current and former smokers was made.
Recent reviews confirm the major role of altered bow-
el microbiota in the pathogenesis of IBD, namely in UC 
(32,33). Nevertheless, the knowledge of how dysbiosis can 
influence the age of onset is still scarce. Despite not being 
the purpose of the current study, we can hypothesize that 
the impact of dysbiosis on the age of onset of UC, if any, 
would probably be more notorious in older patients, in 
whom changes in nutrition, living conditions, motility and 
gut immune function or previous antibiotic exposure that 
can modify gut microbiota are likely.
The effect of ageing in the immune system and in 
inflammatory processes, namely on UC, as well as the 
way they clinically manifest are far from being completely 
understood. Nonetheless, evidence suggests that immune 
senescence present in older patients may be characterized 
by less-robust immune responses, which may influence 
UC behaviour, namely disease extension, severity and 
clinical course (7). The impact of age of onset on disease 
extension is not consensual between studies. While some 
studies, similarly to our results, found no significant dif-
ferences in disease extension between early and late onset 
UC (7,22,27), other found that UC diagnosed in young-
er patients is associated with a more extensive disease 
and even with a higher probability of disease extension 
(24,29). Another aspect that is believed to be influenced 
by the age of diagnosis is disease severity. Even though 
we have not used Montreal Classification for evaluate dis-
ease severity and thus direct comparison between studies 
is limited, we showed that, when diagnosed at younger 
ages, patients should expect a more severe disease. In fact, 
in the early onset group, nearly a quarter of patients were 
steroid-dependent or steroid-refractory, requiring more 
aggressive medical therapies such as thiopurines or bio-
logic agents. On the other hand, in the late onset group, 
approximately three quarters of patients had mild disease 
and only a minority had a more severe disorder. Moreover, 
severe exacerbation of disease needing hospitalization was 
also significantly more common in the early onset group. 
Regarding clinical course, a chronic intermittent disease 
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was significantly more common in younger patients, while 
older patients were more prone to be in remission or have 
mild symptoms after initial high activity. How immune 
system can exactly influence the occurrence of extraintes-
tinal manifestations at difference ages of diagnosis is still 
unknown. In fact, while some authors report them more 
frequently when diagnosis is made earlier in life (15,23), 
other describe a higher incidence in older patients (34). In 
this study, no significant differences were found between 
patients.
Although some specific guidelines for the paediatric 
population exist (35), there are no distinct guidelines for 
the treatment of adults diagnosed before or after the age of 
40 years old. In fact, in both groups, medical management 
should be equally guided by location, extension and severi-
ty of the disease (36). As it is the current first-line treatment, 
topical aminosalicylates have been used in all the patients 
included in our series. However, the use of more inten-
sive medical therapy was significantly different between 
groups, specifically oral aminosalicylates, systemic ste-
roids and thiopurines, which were used more commonly 
in the early onset of disease group. The necessity of more 
aggressive medical therapy in patients diagnosed earlier in 
life has been matter of debate. While some studies report 
results similar to the ones we achieved (37), other reported 
no distinctions among groups (7,22). Less expectedly, but 
as shown by some previous studies (7,22), we confirmed 
no differences regarding anti-TNF agents use between both 
groups. This result should however be interpreted cautious-
ly due to the reduced number of patients on biologic treat-
ment in our series. Contrasting with the majority of other 
studies who report variable percentages of patients, either 
with early or late onset of disease, requiring colectomy with 
ileal pouch-anal anastomosis, our group of patients present 
only one in which colectomy was need for treatment of 
dysplasia and thus comparative analysis was not possible. 
Although some studies report higher colectomy rates in 
patients with early onset disease (27), most studies agree 
that no differences in the rate of colectomy exist between 
early and late onset UC (7,15,22,37). 
In conclusion, this is the first single-centre published 
study focusing in differences between early and late onset 
UC, diagnosed in a Portuguese northern population. When 
diagnosed before the age of 40-years-old, UC preferably 
affects women and has a more severe disease, with more 
frequent hospitalizations and chronic intermittent symp-
toms. On the contrary, UC diagnosed after the 40-years-
old, tends to affect primarily men, with a more indolent 
clinical course, requiring less hospitalizations. This fact 
might have implications in planning timely and individu-
alized future therapeutic strategies.
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